Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma – a patient population with the “greatest unmet need.”
Skip Nav Destination
Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL
December 30, 2021
Content License:Private